Drug Profile

BBT 001

Alternative Names: BBT-001

Latest Information Update: 09 Jun 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Bambusa Therapeutics
Class Bispecific antibodies; Skin disorder therapies
Mechanism of Action Interleukin 31 receptor modulators; Interleukin 4 receptor alpha subunit modulators

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

30 May 2025 US FDA approves IND application for BBT 001 in Atopic dermatitis
30 May 2025 Bambusa Therapeutics plans a phase I trial for Atopic dermatitis in USA
04 Mar 2025 Phase-I clinical trials in Atopic dermatitis in Australia (Parenteral) before March 2025 (Bambusa Therapeutics pipeline, March 2025) (NCT06808477)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com